The PDGF system and its antagonists in liver fibrosis
详细信息 查看全文
- 作者：Erawan Borkham-Kamphorst ; ekamphorst@ukaachen.de" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Ralf Weiskirchen ; rweiskirchen@ukaachen.de" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae
- 关键词：α-SMA ; α-smooth muscle actin ; α2M ; α-2-macroglobulin ; BDL ; bile duct ligation ; Con A ; concanavalin A ; DMN ; dimethylnitrosamine ; ECM ; extracellular matrix ; FSAP ; factor VII-activating protease ; HCC ; hepatocellular carcinoma ; HSC ; hepatic stellate cell(s) ; IL ; interleukin ; MFB ; myofibroblast(s) ; MMP ; matrix metalloproteinase ; PDGF ; platelet-derived growth factor ; PDGFR-α/β ; PDGF receptor type α or β ; PF ; portal fibroblasts ; PTEN ; phosphatase and tensin homolog ; SPARC ; secreted protein acidic and r
- 刊名：Cytokine & Growth Factor Reviews
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：28
- 期：Complete
- 页码：53-61
- 全文大小：1923 K
文摘
- •
PDGF signaling plays important roles in hepatic fibrogenesis.
- •
Blocking of PDGF signaling ameliorates experimental liver fibrogenesis.
- •
Novel therapeutic options for targeting PDGF signaling are available.
- •
These include antagonistic antibodies, aptamers, SOMAmers, receptor tyrosine kinase inhibitors.
- •
These are effective in attenuation of hepatic stellate cell proliferation and fibrosis.
- •
They are on the way from bench to bedside.